open access

Vol 12, No 5 (2016)
Congress abstract / Abstract
Published online: 2017-03-08
Get Citation

ESMO 2016 Congress: Three of the most important studies in the field of immuno-oncology

Dorota Kwapisz
DOI: 10.5603/OCP.2016.0013
·
Oncol Clin Pract 2016;12(5):193-196.

open access

Vol 12, No 5 (2016)
CONGRESS REPORT
Published online: 2017-03-08

Abstract

The 2016 European Society for Medical Oncology (ESMO) annual congress highlighted the latest discoveries in different types of cancer research. Advances in cancer immunotherapy in recent years have caused a paradigm shift in cancer management. Numerous clinical trials results with immunotherapeutic agents (e.g., anti-CTLA-4, anti-PD-1) were presented at the annual ESMO meeting, which will change the treatment approach, especially for patients with melanoma, lung cancer, and head and neck cancer. In this paper three selected studies dedicated to the immuno-oncology field, which were presented during the meeting, will be discussed.

Abstract

The 2016 European Society for Medical Oncology (ESMO) annual congress highlighted the latest discoveries in different types of cancer research. Advances in cancer immunotherapy in recent years have caused a paradigm shift in cancer management. Numerous clinical trials results with immunotherapeutic agents (e.g., anti-CTLA-4, anti-PD-1) were presented at the annual ESMO meeting, which will change the treatment approach, especially for patients with melanoma, lung cancer, and head and neck cancer. In this paper three selected studies dedicated to the immuno-oncology field, which were presented during the meeting, will be discussed.

Get Citation

Keywords

ESMO congress, immuno-oncology, ipilimumab, pembrolizumab, nivolumab

About this article
Title

ESMO 2016 Congress: Three of the most important studies in the field of immuno-oncology

Journal

Oncology in Clinical Practice

Issue

Vol 12, No 5 (2016)

Article type

Congress abstract / Abstract

Pages

193-196

Published online

2017-03-08

DOI

10.5603/OCP.2016.0013

Bibliographic record

Oncol Clin Pract 2016;12(5):193-196.

Keywords

ESMO congress
immuno-oncology
ipilimumab
pembrolizumab
nivolumab

Authors

Dorota Kwapisz

References (14)
  1. www.esmo.org.
  2. Yervoy. Highlights of prescribing information. www.fda.gov.
  3. Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med. 2016; 375(19): 1845–1855.
  4. European Society for Medical Oncology (ESMO) Congress. www.esmo.org (2016).
  5. www.fda.gov.
  6. Mocellin S, Pasquali S, Rossi CR, et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2010; 102(7): 493–501.
  7. Eggermont AMM, Suciu S, Rutkowski P, et al. EORTC Melanoma Group. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. Eur J Cancer. 2016; 55: 111–121.
  8. Opdivo. Highlights of prescribing information. www.fda.gov.
  9. Harrington K, Ferris RL, Shaw J et al. Patient-Reported Outcomes (PROs) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treated with Nivolumab (Nivo) or Investigator’s Choice (IC): CheckMate 141. European Society for Medical Oncology (ESMO) Congress; Copenhagen, Denmark 2016. Abstract LBA4_PR.
  10. Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19): 1856–1867.
  11. https://clinicaltrials.gov.
  12. Reck M, Rodríguez-Abreu D, Robinson AG et al. KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 50%. European Society for Medical Oncology (ESMO) Congress; Copenhagen, Denmark 2016. Abstract LBA8_PR.
  13. Reck M, Rodríguez-Abreu D, Robinson AG, et al. KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19): 1823–1833.
  14. Langer C, Gadgeel S, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. The Lancet Oncology. 2016; 17(11): 1497–1508.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl